Robert M. Verdijk
Erasmus University Rotterdam
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Robert M. Verdijk.
Modern Pathology | 2014
Anna E. Koopmans; Robert M. Verdijk; Rutger W. W. Brouwer; Thierry van den Bosch; Mike M P van den Berg; Jolanda Vaarwater; Christel Kockx; Dion Paridaens; Nicole C. Naus; Mark Nellist; Wilfred van IJcken; Emine Kilic; Annelies de Klein
Uveal melanoma is a lethal cancer with a strong propensity to metastasize. Limited therapeutic options are available once the disease has disseminated. A strong predictor for metastasis is the loss of chromosome 3. Inactivating mutations in BAP1 encoding the BRCA1-associated protein 1 and located on chromosome 3p21.1, have been described in uveal melanoma and other types of cancer. In this study, we determined the prevalence of somatic BAP1 mutations and examined whether these mutations correlate with the functional expression of BAP1 in uveal melanoma tissue and with other clinical, histopathological and chromosomal parameters. We screened a cohort of 74 uveal melanomas for BAP1 mutations, using different deep sequencing methods. The frequency of BAP1 mutations in our study group was 47%. The expression of BAP1 protein was studied using immunohistochemistry. BAP1 staining was absent in 43% of the cases. BAP1 mutation status was strongly associated with BAP1 protein expression (P<0.001), loss of chromosome 3 (P<0.001), and other aggressive prognostic factors. Patients with a BAP1 mutation and absent BAP1 expression had an almost eightfold higher chance of developing metastases compared with those without these changes (P=0.002). We found a strong correlation between the immunohistochemical and sequencing data and therefore propose that, immunohistochemical screening for BAP1 should become routine in the histopathological work-up of uveal melanoma. Furthermore, our analysis indicates that loss of BAP1 may be particularly involved in the progression of uveal melanoma to an aggressive, metastatic phenotype.
Investigative Ophthalmology & Visual Science | 2012
Thomas van den Bosch; Jackelien G.M. van Beek; Jolanda Vaarwater; Robert M. Verdijk; Nicole C. Naus; Dion Paridaens; Annelies de Klein; Emine Kilic
PURPOSE To investigate the relation between patient survival and incrementally increasing percentages of fluorescence in situ hybridization-determined complete loss of chromosome 3 (monosomy 3) and gain of chromosome 8q in primary uveal melanoma cells. METHODS Clinicopathological factors were related to disease-free survival. Fluorescence in situ hybridization was performed using probes on chromosomes 1, 3, 6, and 8. The percentages of UM cells with monosomy 3 or chromosome 8q gain were classified in groups with incrementally increasing percentages and related to disease-free survival. Correlations between clinical factors and cytogenetic aberrations were also analyzed. RESULTS Two-hundred twenty choroidal and ciliary body melanomas were analyzed. The following proved to be significant predictors of survival in univariate analysis: older patient age (P = 0.003); large tumor diameter (P < 0.001); mixed cell type (P = 0.001); presence of closed microvascular loops (P < 0.001); loss of chromosome 1p (P = 0.006); monosomy 3 (P < 0.001); gain of 6p (P < 0.001); and gain of chromosome 8q (P < 0.001). Multivariate Cox analysis displayed monosomy 3 (Hazard ratio [HR] 2.83, P = 0.002) and gain of chromosome 8q (HR 3.13, P = 0.002) as the most important independent prognostic factors of poor survival, followed by older patient age (HR 1.02, P = 0.017). Increasing percentages of monosomy 3 and gain of chromosome 8q in tumor cells showed a correlation with worse prognosis (Log-rank test 49.9 and 40.4, both P < 0.001) and increased number of additional copies of 8q correlated with shorter disease-free interval (Log-rank test 45.7, P < 0.001). CONCLUSIONS A high percentage monosomy 3 and chromosome 8q gain in primary UM cells showed a strong relation with poor disease-free survival compared with low percentage aberrations.
Human Mutation | 2013
Partha Sen; Yaping Yang; Colby Navarro; Iris Silva; Przemyslaw Szafranski; Katarzyna E. Kolodziejska; Avinash V. Dharmadhikari; Hasnaa Mostafa; Harry P. Kozakewich; Debra L. Kearney; John Cahill; Merrissa Whitt; Masha Bilic; Linda R. Margraf; Adrian Charles; Jack Goldblatt; Kathleen Gibson; Patrick E. Lantz; A. Julian Garvin; John K. Petty; Zeina N. Kiblawi; Craig W. Zuppan; Allyn McConkie-Rosell; Marie McDonald; Stacey L. Peterson-Carmichael; Jane T. Gaede; Binoy Shivanna; Deborah Schady; Philippe Friedlich; Stephen R. Hays
Alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV) is a rare and lethal developmental disorder of the lung defined by a constellation of characteristic histopathological features. Nonpulmonary anomalies involving organs of gastrointestinal, cardiovascular, and genitourinary systems have been identified in approximately 80% of patients with ACD/MPV. We have collected DNA and pathological samples from more than 90 infants with ACD/MPV and their family members. Since the publication of our initial report of four point mutations and 10 deletions, we have identified an additional 38 novel nonsynonymous mutations of FOXF1 (nine nonsense, seven frameshift, one inframe deletion, 20 missense, and one no stop). This report represents an up to date list of all known FOXF1 mutations to the best of our knowledge. Majority of the cases are sporadic. We report four familial cases of which three show maternal inheritance, consistent with paternal imprinting of the gene. Twenty five mutations (60%) are located within the putative DNA‐binding domain, indicating its plausible role in FOXF1 function. Five mutations map to the second exon. We identified two additional genic and eight genomic deletions upstream to FOXF1. These results corroborate and extend our previous observations and further establish involvement of FOXF1 in ACD/MPV and lung organogenesis.
The Journal of Pathology | 2015
Debby van Riel; Robert M. Verdijk; Thijs Kuiken
The olfactory nerve consists mainly of olfactory receptor neurons and directly connects the nasal cavity with the central nervous system (CNS). Each olfactory receptor neuron projects a dendrite into the nasal cavity on the apical side, and on the basal side extends its axon through the cribriform plate into the olfactory bulb of the brain. Viruses that can use the olfactory nerve as a shortcut into the CNS include influenza A virus, herpesviruses, poliovirus, paramyxoviruses, vesicular stomatitis virus, rabies virus, parainfluenza virus, adenoviruses, Japanese encephalitis virus, West Nile virus, chikungunya virus, La Crosse virus, mouse hepatitis virus, and bunyaviruses. However, mechanisms of transport via the olfactory nerve and subsequent spread through the CNS are poorly understood. Proposed mechanisms are either infection of olfactory receptor neurons themselves or diffusion through channels formed by olfactory ensheathing cells. Subsequent virus spread through the CNS could occur by multiple mechanisms, including trans‐synaptic transport and microfusion. Viral infection of the CNS can lead to damage from infection of nerve cells per se, from the immune response, or from a combination of both. Clinical consequences range from nervous dysfunction in the absence of histopathological changes to severe meningoencephalitis and neurodegenerative disease. Copyright
Human Mutation | 2013
Yu Sun; Rowida Almomani; Guido J. Breedveld; Gijs W.E. Santen; Emmelien Aten; Dirk J. Lefeber; J. I. Hoff; E. Brusse; Frans W. Verheijen; Robert M. Verdijk; Marjolein Kriek; Ben A. Oostra; M.H. Breuning; Monique Losekoot; J.T. den Dunnen; B.P.C. van de Warrenburg; Anneke Maat-Kievit
Spinocerebellar ataxias are phenotypically, neuropathologically, and genetically heterogeneous. The locus of autosomal recessive spinocerebellar ataxia type 7 (SCAR7) was previously linked to chromosome band 11p15. We have identified TPP1 as the causative gene for SCAR7 by exome sequencing. A missense and a splice site variant in TPP1, cosegregating with the disease, were found in a previously described SCAR7 family and also in another patient with a SCAR7 phenotype. TPP1, encoding the tripeptidyl‐peptidase 1 enzyme, is known as the causative gene for late infantile neuronal ceroid lipofuscinosis disease 2 (CLN2 disease). CLN2 disease is characterized by epilepsy, loss of vision, ataxia, and a rapidly progressive course, leading to early death. SCAR7 patients showed ataxia and low activity of tripeptidyl‐peptidase 1, but no ophthalmologic abnormalities or epilepsy. Also, the slowly progressive evolution of the disease until old age and absence of ultra structural curvilinear profiles is different from the known CLN2 phenotypes. Our findings now expand the phenotypes related to TPP1‐variants to SCAR7. In spite of the limited sample size and measurements, a putative genotype–phenotype correlation may be drawn: we hypothesize that loss of function variants abolishing TPP1 enzyme activity lead to CLN2 disease, whereas variants that diminish TPP1 enzyme activity lead to SCAR7.
Journal of Neurology, Neurosurgery, and Psychiatry | 2008
M.C.Y. de Wit; Johan M. Kros; D. J. J. Halley; I.F.M. de Coo; Robert M. Verdijk; Bart C. Jacobs; Grazia M.S. Mancini
Filamin A is an important gene involved in the development of the brain, heart, connective tissue and blood vessels. A case is presented illustrating the challenge in recognising patients with filamin A mutations. The patient, a 71-year-old woman, was known to have heart valve disease and bilateral periventricular nodular heterotopia when she died of a subarachnoid haemorrhage. Autopsy showed typical cerebral bilateral periventricular heterotopia and vascular abnormalities. Postmortally, the diagnosis of a filamin A mutation was confirmed. Recognition during life may prevent cardiovascular problems and provide possibilities for genetic counselling.
Molecular Biology of the Cell | 2013
Scot C. Leary; Paul A. Cobine; Tamiko Nishimura; Robert M. Verdijk; Ronald R. de Krijger; René de Coo; Mark A. Tarnopolsky; Dennis R. Winge; Eric A. Shoubridge
The study of patient tissues and cell lines shows that SCO1 and SCO2 function collaboratively to generate a redox-dependent signal that is transduced from mitochondria to the cytosol by COX19, where it is relayed to ATP7A to regulate the rate of copper efflux from the cell.
Orbit | 2014
Robert M. Verdijk; Pegah Heidari; Roel Verschooten; Paul L. A. van Daele; Huib J. Simonsz; Dion Paridaens
ABSTRACT Purpose: To determine the relation of orbital xanthogranuloma with IgG4-related disease. Methods: Retrospective consecutive case series over a period of 25 years. We searched our charts for histologically confirmed orbital xanthogranuloma. Patient files were reviewed for clinical and follow up data including presence or absence of systemic non-ophthalmic manifestations of IgG4 related disease. Slides were re-examined and histopathological classification was re-assessed. Sixteen cases of orbital xanthogranuloma were evaluated. Immunohistochemical stains for IgG and IgG4 were performed. Positive immunohistochemical staining required increased IgG4-positive plasma cells in the involved tissues scored as >50 per high-power field, with IgG4/IgG ratio >0.40. Results: According to the criteria described above 8/16 (50%) cases showed increased numbers of IgG4-positive plasma cells in the specimens. Two of these patients may have had signs of systemic disease Conclusion: Raised numbers of IgG4-positive plasma cells are a common finding in histopathological specimens of xanthogranulomatous disease of the orbit and are often not indicative for IgG4 related systemic disease.
Journal of Neuropathology and Experimental Neurology | 2010
Robert M. Verdijk; Michael A. den Bakker; Hendrikus J. Dubbink; Wim C. J. Hop; Winand N. M. Dinjens; Johan M. Kros
Mutations in TP53 underlie the development of malignant peripheral nerve sheath tumors (MPNSTs) in animal models, but there is controversy regarding the extent of TP53 mutations in human MPNSTs. We assessed the TP53 mutation frequency in 145 consecutive cases from our department over 36 years; 88 cases were histologically confirmed as MPNSTs, and corresponding clinical data were reviewed. Mutation analysis of TP53 Exons 4 to 9 on DNA from formalin-fixed, paraffin-embedded specimens was performed by bidirectional DNA sequencing. Tumors were localized in the extremities (n = 34), trunk (n = 34), or head and neck (n = 20). A minority of patients (n = 26, 30%) had neurofibromatosis type 1 (NF1); in these patients, the diagnosis of MPNST was made at younger ages (33 [SD, 3.6] years vs 49 [SD, 2.9] years in NF1 vs non-NF1; p = 0.003). High p53 protein expression was detected in 18 (21%) of 86 cases by immunohistochemistry. TP53 mutations were detected in 17 (24%) of 72 evaluable tumors, of which 36% were from NF1 patients. TP53 mutation and strong p53 immunostaining were positively correlated (p = 0.002); high proliferation indices correlated with cellular epithelioid and storiform growth patterns. These results indicate that TP53 mutations are relatively rare in human MPNST and that they are not positively correlated with the presence of NF1.
Annals of Neurology | 2017
Agnes van Sonderen; Dave L. Roelen; Johannes A. J.A. Stoop; Robert M. Verdijk; Geert W. Haasnoot; Roland D. Thijs; Paul W. Wirtz; Marco W.J. Schreurs; Frans H.J. Claas; Peter A. E. Sillevis Smitt; Maarten J. Titulaer
Leucine‐rich glioma‐inactivated1 (LGI1) encephalitis is an antibody‐associated inflammation of the limbic area. An autoimmune etiology is suspected but not yet proven. We performed human leukocyte antigen (HLA) analysis in 25 nontumor anti‐LGI1 patients and discovered a remarkably strong HLA association. HLA‐DR7 was present in 88% compared to 19.6% in healthy controls (p = 4.1 × 10−11). HLA‐DRB4 was present in all patients and in 46.5% controls (p = 1.19 × 10−7). These findings support the autoimmune hypothesis. An exploratory analysis was performed in a small group of 4 tumor‐LGI1 patients. The strong HLA association seems not applicable in these patients. Therefore, the absence of HLA‐DR7 or HLA‐DRB4 could raise tumor suspicion in anti‐LGI1 patients. Ann Neurol 2017;81:193–198